Clinical trials for Leqembi (generic name: lecanemab) and Kisunla (generic donanemab) have shown some promise for early-stage Alzheimer’s patients, but...
Paper cited: Grashow, R et al. “Perceived Chronic Traumatic Encephalopathy and Suicidality in Former Professional Football Players” JAMA Neurology DOI: 10.1001/jamaneurol.2024.3083 Authorship: In addition...
INDIANAPOLIS, Sept. 2024 /PRNewswire/ — The Ministry of Health, Labour and Welfare Japan has approved Kisunla (generic name: donanemab). Japan is the second...
INDIANAPOLIS /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic...
Type 2 diabetes and prediabetes are associated with accelerated brain ageing, according to a new study from Karolinska Institutet published...
This site was inspired by my Mom’s autoimmune dementia.It is a place where we separate out the wheat from the...
With new medications on the market or in the works for Alzheimer’s disease and other kinds of dementia, a study...
![USA Dementia Diagnosis is Double Trouble [AlzWeek.com]](https://cdnnew.healthlydays.com/wp-content/uploads/2024/08/USA-Dementia-Diagnosis-is-Double-Trouble-AlzWeekcom.jpg)
With new medications on the market or in the works for Alzheimer’s disease and other kinds of dementia, a study...
This site was inspired by my Mom’s autoimmune dementia.It is a place where we separate out the wheat from the...
Kisunla(Donanemab)Leqembi(Lecanemab) Drug ClassMonoclonal antibody. Binds itself to plaque AFTER fibers have clumped together as larger plaques in the brain.Monoclonal antibody....
Kisunla(Donanemab)Leqembi(Lecanemab) Drug ClassMonoclonal antibodytargeting beta-amyloid.Monoclonal antibodytargeting beta-amyloid.ApprovalJuly 2, 2024July 2023Infusions1 / month2 / monthIf scans show clearingOften OK to stop...
![Kisunla Approved by FDA, 2nd Drug to Actually Slow Alzheimer’s [AlzWeek.com]](https://cdnnew.healthlydays.com/wp-content/uploads/2024/07/Kisunla-Approved-by-FDA-2nd-Drug-to-Actually-Slow-Alzheimers.jpg)
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly and Company. (Article continued below video..)...